Medicine Management

As with any other company strategy, access to medicine policies and objectives need to be backed by a strong governance platform and management system. Index 2010 analyzes companies, for example, on the clarity and comprehensiveness of their access to medicine management systems. Read more

Policy and Influence

Pharmaceutical companies have significant leverage to influence markets with potential positive or negative implications for access to medicine. This section looks at the influence of companies through lobbying and advocacy, behavior towards competition and marketing practices to name a few. Read more

Research and Development

R & D remains a key bottleneck for access to medicine, especially in the neglected diseases category as well as insufficient development in the area of product adaptations. In this section, companies' efforts in Innovative R&D, Adaptive R&D and Intellectual Property Sharing are analyzed. Read more

Pricing and Distribution

This technical area covers company efforts in manufacturing, pricing and distribution of products. These areas in turn have a direct impact on the quality, affordability and accessibility of pharmaceutical products in Index Countries. Read more

Licensing and Patenting

Originator companies view patents as a crucial means to recoup R&D costs and foster further innovation which can have significant impact on access to medicine in the Index Countries. Under this area, policies and practices related to patents and intellectual property are analyzed. Read more

Capacity Advancement

Two important barriers to the improvement of access to medicine are the unreliable supply of medicines to markets, and the inconsistent quality of products sold in Index Countries. This area covers initiatives to improve local capacity in supply chains, research & development and manufacturing quality. Read more

Donation and Philanthropy

Product donations and philanthropic activities can have a meaningful impact on global access to medicine. This chapter provides an analysis of pharmaceutical companies practices regarding product donations and philanthropic activities. Read more

Research and Analysis provided by Risk Metrics Group